Tadahiko Igarashi

Indirect-response model for the time course of leukopenia with anticancer drugs*

Hironobu Minami, Yasutsuna Sasaki, Nagahiro Saijo et al. · Clinical Pharmacology & Therapeutics · 1998 · 76 citations

Medicine, Pharmacokinetics, Pharmacology +16

Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11

Y Sasaki, Yasushi Yoshida, Kenichi Sudoh et al. · Japanese Journal of Cancer Research · 1995 · 58 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma

Hidetsugu Kawai, Kiyoshi Ando, Dai Maruyama et al. · Cancer Science · 2021 · 52 citations · Full text

Medicine, Oncology, Pharmacology +13

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of <scp>K</scp>anto CML study group

Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida et al. · American Journal of Hematology · 2014 · 47 citations

Medicine, Oncology, Pharmacology +13

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

Kana Miyazaki, Naoko Asano, Tomomi Yamada et al. · Haematologica · 2019 · 47 citations · Full text

Medicine, Hematology, Oncology +17